Avalon GloboCare Corp. strengthens its capital structure by converting debentures, enhancing Nasdaq compliance and shareholder value.
Quiver AI Summary
Avalon GloboCare Corp. announced the successful conversion of the majority of its outstanding debentures, significantly enhancing its balance sheet and reinforcing its compliance with Nasdaq requirements. The debenture conversion, which amounted to approximately $2.6 million in principal being exchanged for shares of common stock, has effectively eliminated most of the Company's debt. This strategic move is expected to improve financial transparency and support long-term shareholder value as Avalon continues to advance its diagnostic and AI initiatives. The Interim CEO, Meng Li, highlighted that this milestone strengthens the Company’s capital structure and financial flexibility, enabling Avalon to pursue its growth strategies with increased confidence. Additionally, Avalon is involved in developing precision diagnostic consumer products and generative AI software, with ongoing marketing efforts for its KetoAir™ breathalyzer device.
Potential Positives
- Conversion of outstanding debentures strengthens Avalon’s balance sheet by significantly reducing debt, which enhances financial flexibility and capital efficiency.
- Removal of a significant balance-sheet overhang improves financial transparency and supports long-term shareholder value creation.
- Return to compliance with Nasdaq’s minimum stockholders’ equity requirement positions the company to execute strategic growth initiatives with greater confidence.
- Company’s focus on developing precision diagnostic consumer products and advancing intellectual property in AI aligns with growth potential, indicated by their ongoing marketing of the KetoAir™ breathalyzer device, a FDA-registered medical device.
Potential Negatives
- Despite the conversion of debentures improving the capital structure, the announcement indicates the company still relies on financial instruments to manage debt, which may signal underlying financial instability.
- The statement that "substantially all of the converted shares have been sold" could imply that there is a lack of confidence among investors in holding onto the stock, suggesting potential liquidity issues or reduced demand for the shares.
- The reliance on forward-looking statements may raise concerns regarding the certainty of the company’s future financial performance and plans, highlighting that actual results could diverge significantly from expectations.
FAQ
What is the recent announcement from Avalon GloboCare Corp.?
Avalon GloboCare Corp. announced the conversion of a significant portion of its outstanding debentures, strengthening its balance sheet and compliance with Nasdaq.
How does the conversion of debentures benefit Avalon shareholders?
The conversion reduces debt, improves financial transparency, and supports long-term shareholder value creation as Avalon advances its initiatives.
What amount of outstanding debt was converted into shares?
Approximately $2.6 million of the principal from a June 2024 financing was converted into shares of Avalon’s common stock.
What is the significance of this conversion for Avalon’s financial structure?
This conversion eliminates a considerable balance-sheet overhang and enhances capital efficiency and financial flexibility for strategic growth initiatives.
Which product is Avalon currently marketing?
Avalon is currently marketing the KetoAir™ breathalyzer device, registered as a Class I medical device with the FDA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALBT Hedge Fund Activity
We have seen 6 institutional investors add shares of $ALBT stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG added 24,360 shares (+58000.0%) to their portfolio in Q4 2025, for an estimated $29,232
- GEODE CAPITAL MANAGEMENT, LLC added 22,075 shares (+inf%) to their portfolio in Q3 2025, for an estimated $52,538
- PROCYON ADVISORS, LLC added 18,600 shares (+inf%) to their portfolio in Q4 2025, for an estimated $22,320
- EQUITABLE HOLDINGS, INC. removed 14,223 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $33,850
- CITIGROUP INC removed 820 shares (-86.2%) from their portfolio in Q3 2025, for an estimated $1,951
- TOWER RESEARCH CAPITAL LLC (TRC) added 212 shares (+88.0%) to their portfolio in Q3 2025, for an estimated $504
- BANK OF AMERICA CORP /DE/ added 15 shares (+13.3%) to their portfolio in Q3 2025, for an estimated $35
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Conversion Improves Capital Structure, and Reinforces Nasdaq Compliance, Enhancing Shareholder Value
Company Believes That Substantially All of the Converted Shares Have Been Sold
FREEHOLD, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced the conversion of the majority of its outstanding debentures, significantly strengthening the Company’s balance sheet.
The debentures originated from a June 2024 institutional investor convertible note financing with an aggregate principal amount of $2.8 million. Of this amount, $288 thousand of principal was repaid in cash, while the remaining $2.6 million of principal was converted into shares of Avalon’s common stock in accordance with the terms of the debentures, eliminating the majority of Avalon’s outstanding debt. The Company believes that substantially all of the converted shares have been sold.
The Company believes the debenture conversion removes a significant balance-sheet overhang, improves financial transparency, and supports long-term shareholder value creation as Avalon continues advancing its diagnostic, intellectual property, and AI-driven initiatives.
“This conversion represents a meaningful milestone for Avalon,” said Meng Li, Avalon’s Interim Chief Executive Officer and Chief Operating Officer. “By substantially reducing debt, we have strengthened our capital structure, enhanced capital efficiency, and improved our overall financial flexibility. Importantly, this progress aligns with our recent return to compliance with Nasdaq’s minimum stockholders’ equity requirement and positions us to execute our strategic growth initiatives with greater confidence.”
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a diversified company focused on the development of precision diagnostic consumer products, the advancement of intellectual property in generative artificial intelligence publishing and software. Avalon is currently marketing the KetoAir™ breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir™ is registered with the U.S. Food and Drug Administration as a Class I medical device. The Company also continues to focus on advancing its intellectual property portfolio through existing patent applications. In addition, Avalon owns and operates commercial real estate.
For more information about Avalon, please visit www.avalon-globocare.com . Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.
Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements are made based on our expectations and beliefs concerning future events impacting the Company and therefore involve several risks and uncertainties. You can identify these statements by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “should”, “may”, and other words and terms of similar meaning or use of future dates; however, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, as well as the Company’s commercialization, distribution and sales of its products and the product’s ability to compete with other similar products. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the SEC, accessible through the SEC’s website (http://www.sec.gov), including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed or furnished with the SEC. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. The Company disclaims any obligation to update forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. The contents of any website referenced in this press release are not incorporated by reference herein.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9 South, Suite 3100
Freehold, NJ 07728
[email protected]
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
[email protected]
